Drug news
NICE in final guidance rejects Onivyde (nanoliposomal encapsulated irinotecan) in combination with chemotherapy as a cost effective treatment for metastatic pancreatic cancer.- Shire plc.
-The National Institute for Health and Care Excellence (NICE) published final guidance rejecting Onivyde (nanoliposomal encapsulated irinotecan) from Shire plc, in combination with 5-fluorouracil (5-FU) and leucovorin (LV) as a cost effective treatment for metastatic pancreatic cancer after gemcitabine therapy. NICE considered that the established therapy of oxaliplatin + 5FU + LV provided similar median overall survival rates and so the proposed treatment was not cost effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins